Class III β-Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Cancer Research

• Publication date

  2011-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-11-0658PMID 21690572
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials.

  2012cited by this paper
• ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.

  2010cited by this paper
• ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.

  2010cited by this paper
• betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer.

  2010cited by this paper
• Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with Resected Non-small Cell Lung Cancer

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation

  2009cited by this paper
• Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.

  2009cited by this paper
• Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.

  2009cited by this paper
• Pulmonary preneoplasia – sequential molecular carcinogenetic events

  2009cited by this paper
• Overexpression of Class III β-Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma

  2009cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  2009cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• Class III β-Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non–Small Cell Lung Cancer: Analysis of NCIC JBR.10

  2007cited by this paper
• Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.

  2007cited by this paper
• Class III β-Tubulin Overexpression Is a Marker of Poor Clinical Outcome in Advanced Ovarian Cancer Patients

  2006cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

  2006cited by this paper
• Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.

  2005cited by this paper
• Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel

  2005cited by this paper
• Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials

  2005cited by this paper
• Expression of Class III β-Tubulin Is Predictive of Patient Outcome in Patients with Non–Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy

  2005cited by this paper
• Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer

  2003cited by this paper
• The role of beta-tubulin isotypes in resistance to antimitotic drugs.

  2001cited by this paper
• The role of β-tubulin isotypes in resistance to antimitotic drugs

  2001cited by this paper
• The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30

  1996cited by this paper
• The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life.

  1994cited by this paper
• The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

  1993cited by this paper
• Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.

  1993cited by this paper

• TUBB3 EXPRESSION IN NON-SMALL CELL LUNG CANCER: THE REASON FOR IMMUNOHISTOCHEMICAL ASSAY DISCORDANCE AND THE WAY TO OVERCOME IT

  2024cites this paper
• Emerging AXL Inhibitors in Oncology: Chemical and Biological Advances in Targeted Cancer Therapy.

  2024cites this paper
• βIII‐tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c‐Met positive non‐small cell lung cancer cells

  2022cites this paper
• SRC Kinase-Mediated Tyrosine Phosphorylation of TUBB3 Regulates Its Stability and Mitotic Spindle Dynamics in Prostate Cancer Cells

  2022cites this paper
• Lung cancer patients

  2021cites this paper
• Relationship between Expression of β-Tubulin-III Plus ERCC1 in Advanced Ovarian Cancer and Chemotherapy Sensitivity of Paclitaxel Plus Platin Chemotherapy

  2020cites this paper
• Ciliary Genes in Renal Cystic Diseases

  2020cites this paper
• Progress of individualized chemotherapy for gastric carcinoma under the guidance of genetic testing.

  2019cites this paper
• The miR-195 Axis Regulates Chemoresistance through TUBB and Lung Cancer Progression through BIRC5

  2019cites this paper
• Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway

  2018cites this paper
• Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors

  2017cites this paper
• Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers

  2017cites this paper
• An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance

  2017cites this paper
• Identification of molecular targets in vulvar cancers.

  2016cites this paper
• βIII-Tubulin alters glucose metabolism and stress response signaling to promote cell survival and proliferation in glucose-starved non-small cell lung cancer cells.

  2016cites this paper
• Clinical evaluation of postoperative chemotherapy based on genetic testing in patients with stage IIIA non‐small cell lung cancer

  2015cites this paper
• TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis to promote tumorigenesis and anoikis resistance in non-small cell lung cancer.

  2015cites this paper
• Overexpression of stathmin is resistant to paclitaxel treatment in patients with non-small cell lung cancer

  2015cites this paper
• Use of the lung cancer–specific Quality of Life Questionnaire EORTC QLQ‐LC13 in clinical trials: A systematic review of the literature 20 years after its development

  2015cites this paper
• Use of TUBB3 for patient stratification and prognosis in lung cancer

  2015cites this paper
• 靶向治疗背景下非小细胞肺癌传统化疗的地位与发展

  2015cites this paper
• TUBB 3 / b III-Tubulin Acts through the PTEN / AKT Signaling Axis to Promote Tumorigenesis and Anoikis Resistance in Non – Small Cell Lung Cancer

  2015cites this paper
• Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non‐small‐cell lung cancer

  2014cites this paper
• Insulin-like growth factor receptor 1 mRNA expression as a prognostic marker in advanced non-small cell lung cancer.

  2014cites this paper
• The Prognostic Role of the Class III β-Tubulin in Non-Small Cell Lung Cancer (NSCLC) Patients Receiving the Taxane/Vinorebine-Based Chemotherapy: A Meta-Analysis

  2014cites this paper
• Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma.

  2014cites this paper
• Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).

  2014cites this paper
• Déterminants de la prise en charge et du pronostic des cancers broncho-pulmonaires hospitalisés

  2014cites this paper
• βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer

  2014cites this paper
• Gene expression profiles of ERCC1, TYMS, RRM1, TUBB3 and EGFR in tumor tissue from non‐small cell lung cancer patients

  2014cites this paper
• 下调βⅢ-tubulin逆转肺腺癌A549/Taxol细胞株紫杉醇耐药

  2014cites this paper
• miRNA profiling in pancreatic cancer and restoration of chemosensitivity.

  2013cites this paper
• SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers

  2013cites this paper
• Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy.

  2013cites this paper
• Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients

  2013influential citation
• TUBB3/STMN1基因表达与非小细胞肺癌EGFR通路的相关性

  2013cites this paper
• Tubulin: an example of targeted chemotherapy.

  2013cites this paper
• Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.

  2013cites this paper
• SGOL 1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers

  2013cites this paper
• Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.

  2013cites this paper
• Predicting toxicity in advanced lung cancer patients treated with platinum-based chemotherapy

  2013cites this paper
• Microtubules, Drug Resistance, and Tumorigenesis

  2012cites this paper
• Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells

  2012cites this paper
• A biomarker profile for predicting efficacy of cisplatin–vinorelbine therapy in malignant pleural mesothelioma

  2012cites this paper
• High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway

  2012cites this paper
• Translational research to realize the full potential of novel agents – an opportunity for vinflunine?

  2012cites this paper
• Cytoskeleton and Human Disease

  2012cites this paper
• βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer

  2012cites this paper
• Molecular Medicine in Practice High TUBB 3 Expression , an Independent Prognostic Marker in Patients with Early Non – Small Cell Lung Cancer Treated by Preoperative Chemotherapy , Is Regulated by KRas Signaling Pathway

  2012cites this paper